CARD 6 Activators

Compounds like Z-VAD-FMK, which inhibits caspases, and proteasome inhibitors such as MG132, can indirectly affect CARD 6's involvement in apoptotic signaling by modulating the activity of proteins in the apoptotic cascade. Given CARD 6's role in regulating caspase activation, these compounds might impact its function in apoptosis regulation.

Furthermore, compounds targeting NF-κB signaling, such as Parthenolide, BAY 11-7082, JSH-23, Sulforaphane, PDTC, IKK Inhibitor XII, SN50, QNZ, and TPCA-1, could influence CARD 6's activity in NF-κB-mediated signaling pathways. These compounds work through various mechanisms, including inhibiting NF-κB activation, blocking IκB kinase activity, and preventing NF-κB nuclear translocation. Since CARD 6 is implicated in NF-κB signaling, modulation of this pathway could affect its functional role in cellular responses to inflammation and stress. Additionally, Anakinra, by influencing the IL-1/IL-1R signaling pathway, can have indirect implications on NF-κB activation, thereby potentially impacting CARD 6's role in this pathway.